7 Overstated
Autologous stem cell levels drop dramatically after age 40, making them ineffective for extensive tissue repair.
"Bob said, "Listen, using your own stem cells is a waste of time. After 40, they drop through the floor." He said, "If you're doing an elbow or an ankle or something, maybe." But he said, "This is really extensive. You need four-day-old stem cells."" (said at 0:04:04)
While scientific literature confirms that donor aging correlates with a gradual decline in the clonogenic and proliferative potential of bone marrow-derived mesenchymal stem cells (MSCs), claiming that autologous stem cells 'drop through the floor' after age 40 or are a 'waste of time' for tissue repair is an overstatement. Systematic reviews evaluating chronological age and stem cell potency show that age-related functional changes occur gradually across decades rather than dropping precipitously at age 40, and outcomes regarding differentiation and regenerative potential remain heterogeneous across tissue sources (such as adipose-derived vs. bone marrow-derived stem cells).
In the three days following the spring transition into daylight saving time, heart attacks increase by an average of 24% across 70 countries.
"when we spring forward and we lose just one hour of sleep, in those 70 countries over the next three days, heart attacks increase like clockwork, on average, 24%." (said at 0:11:41)
The claim misrepresents a specific finding from a single US regional registry study as a global 70-country average. The cited 24% figure originates from a study of hospital admissions in Michigan (USA), which found a 24% increase in acute myocardial infarction admissions specifically on the single Monday immediately following the spring transition, with no significant increase on subsequent days and no increase in total weekly admissions. Comprehensive systematic reviews and meta-analyses pooling data across multiple countries report a far more modest increase of roughly 3% to 5% in relative risk following the spring transition (pooled RR ~1.04 to 1.05), while larger registry evaluations have found no statistically significant difference in weekly heart attack incidence.
- context: Daylight savings time and myocardial infarction. (Open heart 2014) · cited 85x in the literature
"There was no difference in the total weekly number of PCIs performed for AMI for either the fall or spring time changes in the time period analysed. After adjustment for trend and seasonal effects, the Monday following spring time changes was associated with a 24% increase in daily AMI counts (p=0.011), and the Tuesday following fall changes was conversely associated with a 21% reduction (p=0.044). No other weekdays in the weeks following DST changes demonstrated significant associations." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Daylight Saving Time and Acute Myocardial Infarction: A Meta-Analysis. (Journal of clinical medicine 2019) · cited 88x in the literature
"Seven studies (>115,000 subjects) were included in the analyses. A significantly higher risk of AMI (Odds Ratio: 1.03; 95% CI: 1.01⁻1.06) was observed during the two weeks following spring or autumn DST transitions. However, although AMI risk increased significantly after the spring shift (OR: 1.05; 1.02⁻1.07), the incidence of AMI during the week after winter DST transition was comparable with control periods (OR 1.01; 0.98⁻1.04)." (abstract, results, passage verified)
pubmedfull study (doi) - contradicts: Daylight Saving Time Transitions and Risk of Heart Attack. (Deutsches Arzteblatt international 2024) · cited 6x in the literature
"Twelve studies from ten countries were included in the meta-analysis... The pooled relative risk (RR) of AMI after daylight saving time onset (spring) was 1.04 (95% confidence interval [1.02; 1.07], I2: 57.3%), and 1.02 ([0.99; 1.05], I2: 51.6%) after daylight saving time offset (autumn)." (abstract, results)
pubmedfull study (doi)
When falling back for daylight saving time and gaining one hour of sleep, heart attacks decrease by 21% across countries that observe it.
"When we fall back and get just one more hour of sleep, in all those countries, heart attacks dropped 21%." (said at 0:11:51)
The speaker claims that during the autumn 'fall back' clock change, heart attacks drop by 21% "in all those countries" that observe daylight saving time (DST).
Large systematic reviews and meta-analyses examining global data show either no significant change or at most a non-significant, very tiny difference (~0% to 2%) in overall acute myocardial infarction (AMI) incidence during the autumn transition (PMID: 38888468, 30909587).
The specific figure of a 21% reduction originates from a single study analyzing hospital data in Michigan (Sandhu et al., 2014; PMID: 25332784). However, this 21% reduction was observed only on a single day (the Tuesday following the fall transition), not as a weekly total or an overall effect, and certainly not across all countries observing DST. The total weekly rate of heart attack admissions in that study did not differ significantly following the fall transition.
Sugar acts as a neuroinflammatory agent, causes cardiac disease, and accelerates cancer growth.
"gotten rid of sugar, right? It's like sugar equals poison, it's a neuroinflammatory, it causes cardiac disease, it feeds cancer, there are so many reasons." (said at 0:20:28)
The claim bundles several health effects of dietary sugar into broad, definitive assertions ('sugar equals poison', 'neuroinflammatory', 'causes cardiac disease', 'feeds cancer'). Large-scale systematic and umbrella reviews confirm that high dietary intake of added sugar and sugar-sweetened beverages is associated with increased risks of cardiovascular disease (such as coronary heart disease), adiposity, metabolic dysfunction, and certain cancers. Furthermore, preclinical and mechanistic reviews note that chronic high sugar intake can promote neuroinflammation and blood-brain barrier dysfunction via advanced glycation end products, oxidative stress, and insulin resistance. However, describing sugar categorically as a 'poison' that directly 'feeds cancer' overstates the evidence: glucose is an essential cellular metabolic substrate, and the epidemiological link between high sugar intake and cancer is largely indirect—mediated through excess caloric intake, obesity, hyperinsulinemia, and chronic inflammation rather than sugar directly accelerating cancer growth in isolation.
- context: Dietary sugar consumption and health: umbrella review. (BMJ (Clinical research ed.) 2023) · cited 331x in the literature
"Significant harmful associations between dietary sugar consumption and 18 endocrine/metabolic outcomes, 10 cardiovascular outcomes, seven cancer outcomes, and 10 other outcomes (neuropsychiatric, dental, hepatic, osteal, and allergic) were detected... High dietary sugar consumption is generally more harmful than beneficial for health, especially in cardiometabolic disease." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: The impact of high-sugar diets on central nervous system disorders: mechanisms, pathogenes… (Annals of medicine 2025) · cited 10x in the literature
"High-sugar diets directly contribute to weight gain, insulin resistance, and chronic hyperglycemia, which drive cardiovascular complications and systemic inflammation through advanced glycation end products (AGEs) and oxidative stress. Emerging evidence highlights their critical role in the pathogenesis of central nervous system (CNS) disorders... likely mediated through obesity-associated chronic inflammation, T2DM-driven blood-brain barrier dysfunction, and neuroinflammation." (abstract, background, passage verified)
pubmedfull study (doi)
A 20- to 24-month-old mouse runs a maximum of 0.25 km compared to 1 km for a young mouse, but 14 days of NMN treatment allows the older mouse to run 2 to 3 km.
"if you take an old mouse, meaning like a 70-year-old equivalent as a human, is about a 20- to 24-month mouse, as I'm sure you know, and you put them on, you know, a running platform, they can go maximum of a quarter of a kilometer, but a young, powerful mouse can do four times as much, a full kilometer. Well, 14 days on NMN, and now the NAD gets in, the absorption is about 30%, and that same animal that's equivalent of a 70-year-old animal will run two to three kilometers" (said at 0:33:13)
The speaker is referring to a preclinical mouse study from their laboratory (Das et al., 2018, PMID 29570999). In that study, 20-month-old mice ran approximately 240 meters (0.24 km) to exhaustion on a treadmill, compared to young mice running about 1,000 meters (1 km). Treatment with nicotinamide mononucleotide (NMN) significantly improved treadmill running endurance in the older mice (increasing distance and time by approximately 56% to 80%, reaching ~400–450 meters), but it did not enable them to run 2 to 3 kilometers. The claim substantially exaggerates the measured effect size, and the finding is restricted to animal models.
Bowhead whales can live up to 200 years and Greenland sharks can live over 500 years.
"you know, the bowhead whale lives 200 years old, you know, the Greenland shark can live 500-plus years old." (said at 0:48:33)
The speaker bundles two longevity claims. The claim that bowhead whales can live approximately 200 years is supported; genomic and biochemical studies establish that bowhead whales (Balaena mysticetus) have an estimated maximum lifespan exceeding 200 years, making them the longest-lived mammal. However, the claim that Greenland sharks live '500-plus years' is overstated. Landmark radiocarbon dating of Greenland shark (Somniosus microcephalus) eye lenses estimated the lifespan of the largest individual at 392 ± 120 years (a 95.4% probability range of roughly 272 to 512 years). While 512 years represents the extreme upper statistical bound of the confidence interval, the mean estimate is approximately 390 years, not a definitive 500+ years.
CRISPR gene editing injected into the back of the eye has been used to treat a specific form of congenital blindness.
"We've seen CRISPR uh being used with an injection in the back of the eye uh to cure a specific form of congenital blindness." (said at 1:01:45)
In vivo CRISPR-Cas9 gene editing has indeed been delivered via subretinal injection (into the back of the eye) in clinical trials to treat a specific form of congenital blindness: CEP290-associated inherited retinal degeneration (Leber congenital amaurosis type 10). In the phase 1-2 BRILLIANCE trial (n=14), subretinal injection of EDIT-101 led to meaningful improvements in visual acuity, photoreceptor sensitivity, or mobility in 64% of participants without serious treatment-related adverse events. However, describing the therapy as having been used to 'cure' congenital blindness overstates the outcome: treatment resulted in partial improvements in visual function in a subset of patients rather than a complete restoration or cure of blindness.
- partial: Gene Editing for CEP290 -Associated Retinal Degeneration. (The New England journal of medicine 2024) · cited 217x in the literature
"We performed a phase 1-2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290-associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye... Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test." (abstract, results)
pubmedfull study (doi)
12 Needs context
Spinal fusion surgery for chronic back pain does not work at least half of the time.
"They were going to, you know, lock up, you know, give him a spinal fusion, which as I'm sure you know doesn't usually work, at least half the time, and if it does, gives you limited mobility." (said at 0:05:34)
Spinal fusion for chronic low back pain associated with degenerative disc disease has substantial evidence demonstrating limited clinical superiority over intensive non-operative rehabilitation, along with significant complication rates and frequent persistent pain (often termed failed back surgery syndrome). Systematic reviews and meta-analyses of randomized trials indicate that lumbar fusion yields little to no clinically meaningful difference in pain or disability scores compared to non-operative multidisciplinary care, although quantifying this strictly as 'failing at least half the time' requires qualification based on how success (e.g., pain reduction thresholds versus return-to-work or complication rates) is measured.
The human placenta is a rich source of pluripotent stem cells that can differentiate into heart, liver, or brain cells.
"You can have what's called a pluripotent stem cell, which can form a cell in your heart or your liver or your brain, and the placenta is actually a rich source of that." (said at 0:07:52)
The placenta is an abundant source of perinatal stem cells, including human amniotic epithelial cells (hAECs) and placental mesenchymal stem cells, which originate from the epiblast and exhibit broad multi-lineage differentiation potential across all three embryonic germ layers (capable of forming hepatocyte/liver-like, neural/brain-like, and cardiac/heart-like lineages). However, scientifically, these naturally isolated placental cells are technically classified as multipotent perinatal stem cells rather than fully pluripotent stem cells (like embryonic stem cells or induced pluripotent stem cells), because they generally do not form teratomas in vivo.
Men who sleep 4 to 5 hours a night typically have testosterone levels equivalent to someone 10 years older.
"He also showed me that a man who sleeps four to five hours a night usually has testosterone levels of a person 10 years older than they are." (said at 0:12:02)
Controlled laboratory research demonstrates that restricting sleep to 5 hours per night for one week reduces daytime testosterone levels in young healthy men by approximately 10% to 15%. Because normal aging is associated with an average testosterone decline of roughly 1% to 2% per year, this acute reduction represents an endocrine profile comparable to 10 to 15 years of aging. However, this comparison stems from short-term laboratory sleep-restriction protocols in small cohorts of young men rather than long-term epidemiological observations of habitual short sleepers.
A National Cancer Institute study on 100,000 people found that stage 3 or 4 cancer diagnosis carries an 80% mortality rate, whereas stage 1 or 2 diagnosis carries an 80% to 99.9% survival rate.
"So, you know, the National Cancer Society did a study on 100,000 people, and they found that if you get something at stage 3 or stage 4, you have an 80% chance of dying—I like, look at it, 20% chance of living, or what to do. But their point is well made: it's really hard to turn around. If you get at stage 1 or 2, you have an 80 to 99.9% chance of survival." (said at 0:24:31)
The speaker conflates organizational names ('National Cancer Society', combining the American Cancer Society and the National Cancer Institute) and describes broad registry benchmarks as a single '100,000-person study.' Across large population-based registries such as the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program and American Cancer Society annual reports, aggregate 5-year relative survival varies widely by cancer type. For many common cancers (such as breast, prostate, melanoma, and colorectal cancer), early-stage (localized, Stage I–II) detection is associated with 5-year relative survival rates between 80% and >99%, whereas advanced metastatic disease (distant, Stage IV) frequently exhibits 5-year relative survival of approximately 15% to 35% (corresponding to an ~65% to 85% mortality rate). However, survival differs dramatically by specific histology, organ of origin, and molecular subtypes rather than following a uniform cross-cancer rule.
Cellular NAD levels decline substantially after age 40 and into the 50s, reducing the activity of sirtuin enzymes.
"NAD is sort of a fuel in the cell that powers these sirtuins. And we can talk more in detail here, but the NAD in your in your mitochondria inside your cells, you know, is pretty good in your in your teens, 20s, and 30s, but then in your 40s into your 50s, it falls off rapidly. So just when you need more active sirtuins as the DNA damage is increasing, the fuel supply for the sirtuins starts plummeting, and then all of a sudden you're not able to, you know, control your epigenome and we get aging." (said at 0:30:36)
Nicotinamide adenine dinucleotide (NAD+) is an essential co-substrate for sirtuin enzymes (NAD+-dependent deacetylases) and poly(ADP-ribose) polymerases (PARPs). Human tissue studies demonstrate that cellular NAD+ levels and SIRT1 activity decline progressively with age, inversely correlating with accumulated DNA damage and PARP activation. However, characterizing this as a sudden 'plummet' or rapid drop-off specifically localized to one's 40s and 50s oversimplifies what human cross-sectional data show as a continuous, gradual decline across adulthood.
Sirtuins require NAD for fuel, and NAD requires NMN as a precursor.
"And the sirtuins need the NAD for fuel, but NAD needs NMN, as I know you know, as the precursor to make all that possible." (said at 0:32:20)
The biochemical relationship described is fundamentally accurate with respect to the mammalian NAD+ salvage pathway. Sirtuins are a family of deacetylases and deacylases that strictly require NAD+ as an obligate co-substrate (which is consumed during the reaction, colloquially described as 'fuel'). In turn, nicotinamide mononucleotide (NMN) is the direct intermediate produced by the rate-limiting enzyme NAMPT in the primary NAD+ salvage pathway before conversion to NAD+ by NMN adenylyltransferases. However, NAD+ can also be synthesized via alternative pathways using other dietary precursors, such as tryptophan (de novo pathway) and nicotinic acid (Preiss-Handler pathway).
A study by the Rabinowitz lab demonstrated that high doses of NAD precursors NR and NMN failed to raise NAD levels in tissues outside the liver in animals.
"there was a a study, I think it was the Rabinowitz lab, um, published that—this was in animals—that, you know, that even really, really high doses of both of these precursors, NAD precursors, both NR and NMN, were unable to raise NAD levels in other tissues outside of the liver. So muscle, brain, for example, there was no um change" (said at 0:36:22)
A landmark 2018 isotope-tracing flux study from the Rabinowitz laboratory (Liu et al., Cell Metabolism) demonstrated in mice that orally administered nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are largely degraded and metabolized to nicotinamide by the gut and liver during first-pass metabolism, failing to deliver intact NR or NMN to extrahepatic tissues like muscle. However, when administered intravenously, intact NR and NMN did reach peripheral tissues. Furthermore, the circulating nicotinamide released by the liver after oral dosing can still be utilized by peripheral tissues to synthesize NAD via salvage pathways.
Average human life expectancy was under 40 years a century ago and is currently in the upper 70s.
"So a hundred years ago, the average lifespan was, you know, under 40. Today it's in the upper 70s" (said at 0:45:35)
The speaker's general characterization captures historical demographic trends, but combines global historical estimates with developed-world modern figures and refers to 'lifespan' rather than life expectancy at birth. A century ago (early 20th century), global life expectancy at birth was estimated to be under 35–40 years, heavily driven down by high infant and childhood mortality rather than a maximum biological lifespan ceiling of 40. Today, global average life expectancy at birth has reached approximately 73.5 years (low-to-mid 70s), while life expectancies in the upper 70s and 80s specifically characterize developed and high-income nations.
A study from the London School of Business, Harvard, and Oxford found that adding one year of healthy lifespan globally is worth $38 trillion to the global economy.
"there was uh about six months ago a study done out of London School of Business, Harvard, and Oxford that said adding just one year of healthy lifespan to every human on the planet is worth $38 trillion to the global economy." (said at 1:15:20)
A 2021 study published in Nature Aging by researchers from London Business School, the University of Oxford, and Harvard Medical School (Scott, Ellison, and Sinclair) estimated that slowing aging to increase life expectancy by 1 year is worth $38 trillion. However, this economic valuation—calculated using a Value of Statistical Life (VSL) framework—applied specifically to the United States population, rather than the entire global population or global gross domestic product.
50 years ago the global fertility rate was approximately 5.4 children per family, compared to about 2.4 globally today.
"Back 50 years ago, the average number of children per family was like 5.4 children per family. Today globally it's at about 2.4." (said at 1:16:25)
The speaker accurately describes the dramatic global demographic transition over recent decades, though with minor imprecisions in terminology and historical figures. Demographers measure this using the total fertility rate (TFR), defined as the average number of livebirths per woman across reproductive years, rather than "per family." Comprehensive demographic assessments (such as the Global Burden of Disease studies) show that global TFR was approximately 4.7 to 5.0 in the mid-20th century (and around 4.5–4.8 fifty years ago in the early 1970s) and has declined to approximately 2.3–2.4 in recent years (2.4 in 2017 and 2.31 in 2019).
The monoclonal antibody Repatha (evolocumab) blocks the PCSK9 protein in the liver and reduces LDL cholesterol levels by half.
"I take a monoclonal antibody called Repatha, that this antibody is manufactured in a vat in New York. And um I get an injector, and every two weeks I inject about 5 mL of this of this these antibodies into my into my my leg, and those antibodies go to my liver and they block a protein called PCSK9, which is the protein that produces LDL, the bad type of cholesterol in your bloodstream. And this Repatha reduces my cholesterol, my LDL levels by a half" (said at 1:21:45)
Evolocumab (Repatha) is a human monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to an approximate 50% to 60% reduction in low-density lipoprotein (LDL) cholesterol. In the landmark phase 3 FOURIER trial involving 27,564 patients, evolocumab produced a 59% mean reduction in LDL cholesterol compared to placebo (PMID: 28304224). However, the speaker's description of the mechanism requires qualification: PCSK9 does not produce LDL cholesterol; rather, it binds to low-density lipoprotein receptors (LDLR) on hepatocytes and promotes their lysosomal degradation, reducing the liver's capacity to clear circulating LDL. Inhibiting PCSK9 prevents receptor breakdown, increasing hepatic clearance of LDL from the bloodstream. Additionally, standard biweekly dosing is 140 mg in 1.0 mL (rather than 5 mL).
Moderna designed its COVID-19 mRNA vaccine within 24 hours of receiving the SARS-CoV-2 genetic sequence from Wuhan.
"the sequence gets emailed over from Wuhan to our labs. I know from talking to Stéphane, there was a a vaccine designed within 24 hours." (said at 1:26:23)
Following the identification of the outbreak in Wuhan and the public release of the SARS-CoV-2 genomic sequence on January 11, 2020, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center and Moderna finalized the sequence design for the mRNA-1273 vaccine within approximately 48 hours (by January 13, 2020). The claim accurately reflects the rapid, sequence-directed design process of the vaccine, though the design timeline was completed over approximately two days rather than strictly within 24 hours.
- context: An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development (Medical Science Monitor 2020) · cited 247x in the literature
"The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US)." (abstract, passage verified)
openalexfull study (doi)
18 Supported by research
Using a sauna four to seven times per week significantly reduces the risk of heart attack, stroke, and lowers blood pressure.
"I had no idea the research that showed four to seven times a week could change completely the profile of you having a heart attack or a stroke, the changing of blood pressure." (said at 0:13:10)
The claim is supported by longitudinal cohort data from the Kuopio Ischemic Heart Disease Risk Factor Study (KIHD) in Finland. These prospective observational studies demonstrated that individuals using a sauna 4 to 7 times per week had a significantly lower risk of cardiovascular mortality, sudden cardiac death, stroke, and incident hypertension compared to those who used a sauna once per week. Specifically:
1. **Heart attack / Cardiovascular mortality:** Men who used the sauna 4 to 7 times per week had an adjusted hazard ratio (HR) of 0.37 (95% CI, 0.18–0.75) for sudden cardiac death and 0.23–0.30 for overall cardiovascular disease mortality compared to those taking 1 session per week.
2. **Stroke:** Men and women participating in 4 to 7 sauna sessions per week had an adjusted HR for incident stroke of 0.38 (95% CI, 0.18–0.81).
3. **Blood pressure / Hypertension:** Frequent sauna bathing (4–7 times per week) was associated with a 47% lower risk of incident hypertension (adjusted HR 0.53, 95% CI, 0.28–0.98).
Because these data stem from observational cohort studies rather than randomized controlled trials, certainty is graded as low due to potential residual confounding (e.g., self-selection bias, general health status, lifestyle factors). Nevertheless, the statistical findings directly mirror the speaker's claim.
- supports: Association between sauna bathing and fatal cardiovascular and all-cause mortality events. (JAMA internal medicine 2015) · cited 288x in the literature
"After adjustment for CVD risk factors, compared with men with 1 sauna bathing session per week, the hazard ratio of SCD was 0.78 (95% CI, 0.57-1.07) for 2 to 3 sauna bathing sessions per week and 0.37 (95% CI, 0.18-0.75) for 4 to 7 sauna bathing sessions per week (P for trend = .005)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Sauna Bathing and Incident Hypertension: A Prospective Cohort Study. (American journal of hypertension 2017) · cited 103x in the literature
"compared to participants reporting 1 sauna session per week, the hazard ratio for incident hypertension in participants reporting 2 to 3 sessions and 4 to 7 sessions was 0.76 (95% confidence interval: 0.57-1.02) and 0.54 (0.32-0.91), respectively." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Sauna bathing reduces the risk of stroke in Finnish men and women: A prospective cohort st… (Neurology 2018) · cited 76x in the literature
"Compared with participants who had one sauna bathing session per week... After further adjustment for established cardiovascular risk factors and other potential confounders, the corresponding HR (95% CI) was 0.39 (0.18-0.84) and this remained persistent on additional adjustment for physical activity and socioeconomic status at 0.38 (0.18-0.81)." (abstract, results)
pubmedfull study (doi)
In a Veterans Administration trial of arthroscopic knee surgeries with sham controls, patients receiving sham surgery experienced equal pain relief and mobility after one year compared to those receiving real surgery.
"For knee surgeries, they decided to do a third of the surgeries as sham surgeries, placebo surgeries. They just put a mark, sewed the person up, but did nothing to the knee. A year later, the patients that had no treatment but thought they had had no pain, talked about how mobile they were compared to the ones that were—they don't even fund it anymore." (said at 0:17:50)
A landmark randomized, double-blind, placebo-controlled trial conducted at the Houston Veterans Affairs Medical Center evaluated 180 patients with knee osteoarthritis assigned to arthroscopic debridement, arthroscopic lavage, or sham surgery (skin incisions and simulated surgery without arthroscope insertion). At one and two years of follow-up, patients in the sham surgery group experienced equivalent improvements in pain and functional mobility compared to patients who received active arthroscopic debridement or lavage, with no statistically significant differences across any assessed time points.
- supports: A controlled trial of arthroscopic surgery for osteoarthritis of the knee. (The New England journal of medicine 2002) · cited 2158x in the literature
"At no point did either of the intervention groups report less pain or better function than the placebo group. For example, mean (+/-SD) scores on the Knee-Specific Pain Scale (range, 0 to 100, with higher scores indicating more severe pain) were similar in the placebo, lavage, and débridement groups: 48.9+/-21.9, 54.8+/-19.8, and 51.7+/-22.4, respectively, at one year (P=0.14 for the comparison between placebo and lavage; P=0.51 for the comparison between placebo and débridement) and 51.6+/-23.7, 53.7+/-23.7, and 51.4+/-23.2, respectively, at two years (P=0.64 and P=0.96, respectively)." (abstract, results, passage verified)
pubmedfull study (doi)
The GRAIL Galleri liquid biopsy test can identify circulating cell-free DNA signals for 50 different types of cancer from a routine blood draw.
"Besides the full-body MRI, which is looking for cancers, we do a GRAIL, you know, liquid biopsy, which can find 50 different cancers in your bloodstream. It turns out as cancer cells are growing and dividing very rapidly, some of the cells rupture and you get free-floating DNA in the bloodstream. Well, GRAIL, which is now part of Illumina, started by Jeff Huber—we can we can tell his story—um, they were able to determine and find from a blood draw any number of 50 different cancer DNA sequences and and tell you you've got cancer someplace in your body." (said at 0:22:26)
The GRAIL Galleri multi-cancer early detection (MCED) test analyzes targeted methylation patterns of circulating cell-free DNA (cfDNA) in peripheral blood. In the clinical validation substudy of the Circulating Cell-free Genome Atlas (CCGA) study (NCT02889978; n = 4,077), the test demonstrated high specificity (99.5%) and detected cancer signals across more than 50 different cancer types, while accurately predicting the tissue/organ of origin in 88.7% of true positive cases.
- supports: Clinical validation of a targeted methylation-based multi-cancer early detection test usin… (Annals of oncology : official journal of the European Society for Medical Oncology 2021) · cited 1007x in the literature
"The Circulating Cell-free Genome Atlas study (CCGA; NCT02889978) was a prospective, case-controlled, observational study and demonstrated that a blood-based MCED test utilizing cell-free DNA (cfDNA) sequencing in combination with machine learning could detect cancer signals across multiple cancer types and predict cancer signal origin (CSO) with high accuracy... Cancer signals were detected across >50 cancer types." (abstract, background and results, passage verified)
pubmedfull study (doi) - supports: Real-world data and clinical experience from over 100,000 multi-cancer early detection tes… (Nature communications 2025) · cited 13x in the literature
"To assess real-world performance, we evaluated the Galleri® MCED test (GRAIL, Inc.) across 111,080 individuals (median age 58 years, 55.5% males). This MCED test analyzes methylation patterns of cell-free DNA to detect presence of a cancer signal and predict the anatomical cancer signal origin (CSO) to facilitate diagnostic evaluation." (abstract, results, passage verified)
pubmedfull study (doi)
Sirtuin enzymes are responsible for controlling the epigenome and facilitating DNA repair, but become diverted from epigenetic maintenance as cumulative DNA damage increases with age.
"Now, it turns out that the control of your epigenome, in part, is handled by seven sirtuin genes and seven sirtuin enzymes, and those sirtuins have two primary functions in life. Number one, they control your epigenome. They control which of your genes are on and which of your genes are off. The other thing it does, which is massively significant for your life, is they facilitate DNA repair. And so as we're getting older and we're exposed to radiation—you know, flying in airplanes, or smoke, or, you know, chemicals in the environment—and we start getting accumulating more and more DNA damage, your sirtuins are spending more and more time repairing your DNA instead of controlling which genes are on and which genes are off." (said at 0:29:42)
The speaker accurately describes the relocalization of chromatin modifiers (RCM) hypothesis of aging, specifically demonstrated with mammalian sirtuins. Mammals possess seven sirtuins (SIRT1–SIRT7) that regulate histone modifications, epigenetic gene silencing, and genomic maintenance. Research in cell and mouse models demonstrates that sirtuins such as SIRT1 normally repress gene expression across the genome, but dissociate from their baseline loci and relocalize to DNA double-strand breaks to facilitate repair. Over time, recurring and cumulative DNA damage diverts these chromatin-modifying enzymes away from their baseline epigenetic regulatory functions, leading to transcriptional changes and loss of epigenetic maintenance characteristic of aging. Because these mechanistic data are derived from preclinical cellular and animal models, the GRADE certainty is very low.
- supports: SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression du… (Cell 2008) · cited 848x in the literature
"Using embryonic stem cells, we show that mammalian Sir2, SIRT1, represses repetitive DNA and a functionally diverse set of genes across the mouse genome. In response to DNA damage, SIRT1 dissociates from these loci and relocalizes to DNA breaks to promote repair, resulting in transcriptional changes that parallel those in the aging mouse brain. Increased SIRT1 expression promotes survival in a mouse model of genomic instability and suppresses age-dependent transcriptional changes. Thus, DNA damage-induced redistribution of SIRT1 and other chromatin-modifying proteins may be a conserved mechanism of aging in eukaryotes." (abstract, results, passage verified)
pubmedfull study (doi)
Cleerly's AI-enabled coronary computed tomography angiography (CCTA) analysis can predict heart attacks up to five years in advance by quantifying soft coronary plaque.
"So he explained to me how it opens up the arteries and how you get this score, and they can predict a heart attack five years in advance and show you what to do." (said at 0:25:46)
AI-guided quantitative coronary computed tomography angiography (AI-QCT, including platforms like Cleerly) quantifies coronary plaque burden and composition, specifically noncalcified (soft) plaque and luminal stenosis. Multicenter prospective observational data, such as the CONFIRM2 registry (median 4.3 years follow-up), demonstrate that AI-derived noncalcified plaque volume and stenosis severity independently predict major adverse cardiovascular events and myocardial infarction over an approximate 5-year horizon, significantly improving risk discrimination over traditional cardiovascular risk scores and guiding targeted medical therapy.
SARS-CoV-2 enters the mitochondria and depletes cellular energy, driving long-term fatigue.
"because I'm sure you know with COVID, it goes into your mitochondria and basically steals some of the energy, that's part of the problem with fatigue" (said at 0:34:48)
Research demonstrates that SARS-CoV-2 viral components (such as the envelope E protein) localize to host cell mitochondria, disrupting mitochondrial membrane potential, electron transport chain activity, and metabolic homeostasis. Clinical studies in patients with post-acute COVID-19 and Long COVID show impaired mitochondrial oxidative phosphorylation, decreased ATP generation, and mitochondrial dysfunction, which are key contributing factors to post-COVID fatigue.
- supports: Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients… (Bratislavske lekarske listy 2022) · cited 25x in the literature
"Platelet mitochondrial respiratory chain function, oxidative phosphorylation and endogenous CoQ10 level were reduced in the patients after COVID-19." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Mitochondrial metabolic rescue in post-COVID-19 syndrome: MR spectroscopy insights and pre… (Frontiers in immunology 2025) · cited 15x in the literature
"Post-COVID-19 Condition (PCC), impacting 30-90% of survivors, is characterized by persistent fatigue and metabolic dysfunction, often linked to underlying mitochondrial impairment." (abstract, background, passage verified)
pubmedfull study (doi) - supports: SARS-CoV-2 envelope protein mitochondrial localization reveals host metabolic disruption. (The Journal of biological chemistry 2026)
"We demonstrate that severe acute respiratory syndrome coronavirus 2 E localizes to host cell mitochondria and alters mitochondrial structure, metabolism, and redox homeostasis." (abstract, results, passage verified)
pubmedfull study (doi)
Pulsing the Yamanaka factors throughout the life of accelerated-aging mice resets cellular epigenetic programming without loss of cell identity and reverses aging phenotypes.
"what, you know, Juan Carlos Belmonte's lab and there's some others that have done this in vitro, but he was really the first to show this in an animal, it's called interrupted cellular reprogramming, where um you don't you don't want to make an adult cell lose its identity. You want it to just, you know, basically wipe wipe the program free, but uh but still be the same cell. So you want it to become, you know, younger, so so to speak. So um he showed this proof-of-principle study that adding these Yamanaka factors, but pulsing them throughout uh the life of these animals that are having an acceleration accelerated aging phenotype, he could essentially reverse aging." (said at 0:38:20)
A 2016 study from Juan Carlos Izpisua Belmonte's laboratory (Ocampo et al., Cell) demonstrated that partial cellular reprogramming via short-term, cyclic expression of the Yamanaka factors (Oct4, Sox2, Klf4, and c-Myc; OSKM) in a mouse model of premature aging (progeria) ameliorated cellular and physiological hallmarks of aging, remodeled epigenetic marks, and extended lifespan without inducing pluripotency or loss of somatic cell identity in vivo. Because this proof-of-principle evidence is derived entirely from preclinical animal models and in vitro systems, the GRADE certainty for human application is very low.
David Sinclair's lab restored vision in aged mice with glaucoma using three of the four Yamanaka factors excluding the oncogenic one, published on the cover of Nature in December 2020.
"It was the cover of Nature in December of 2020. It was like, you know, just landmark work where instead of using all four Yamanaka factors, David took in a mouse that had aged out, had become blind with glaucoma and lost its sight, and he gave it three of the four Yamanaka factors without retaining not one of them that causes that causes cancer. Um, and lo and behold, the visual system of the of the mice uh became young again to the point where they regained their vision." (said at 0:39:46)
In December 2020, David Sinclair's laboratory published a study on the cover of Nature demonstrating that viral delivery of three Yamanaka transcription factors (Oct4, Sox2, and Klf4, omitting the oncogene c-Myc) into retinal ganglion cells restored youthful DNA methylation patterns and transcriptomes, promoted axon regeneration, and reversed vision loss in both aged mice and a mouse model of glaucoma. Because this research was conducted exclusively in rodent models, the clinical evidence certainty is very low.
A 2019 PNAS study found a direct positive association between higher levels of optimism and longer lifespan in both men and women.
"there was a PNAS study published back in 2019 that found a direct association between happiness and longevity. And people that had the higher levels, highest levels of happiness lived the longest. They were more likely—and this was true for both men and women—they were more likely—... Optimists, yes. Yeah, that was this was the study, optimists" (said at 0:54:27)
A 2019 study published in the Proceedings of the National Academy of Sciences (PNAS) analyzed data from two large prospective cohorts—women from the Nurses' Health Study and men from the Veterans Affairs Normative Aging Study—and found a dose-dependent positive association between baseline optimism levels and longer lifespan in both sexes. Participants in the highest versus lowest optimism quartiles had significantly longer lifespans (including an estimated 14.9% longer lifespan in women, with similar findings in men) and 1.5- to 1.7-fold greater odds of reaching exceptional longevity (survival to age 85 or older), even after adjusting for demographic factors, health conditions, and health behaviors.
CRISPR gene editing of the PCSK9 gene in the liver of monkeys achieved a 60% reduction in LDL cholesterol levels.
"We just saw uh CRISPR being used to edit the PCSK9 enzyme in in the liver. It's being done in monkeys, hasn't gone to men to humans yet, but it's has the demonstrated ability to reduce your LDL levels by 60%" (said at 1:01:20)
A 2021 preclinical study published in Nature demonstrated that in vivo CRISPR base editing delivered via lipid nanoparticles to target the PCSK9 gene in the liver of cynomolgus monkeys achieved near-complete knockdown of hepatic PCSK9, resulting in an approximate 90% reduction in blood PCSK9 levels and an approximate 60% reduction in LDL cholesterol levels that remained stable for at least 8 months. Because the evidence is derived from a non-human primate animal model, the certainty of evidence is graded as very low.
Partial cellular reprogramming using three Yamanaka factors has been successfully replicated in the cardiac system of mice.
"And it's since been repeated in the cardiac system of mice." (said at 0:40:00)
Animal research confirms that partial cellular reprogramming using the three Yamanaka factors (OSK: OCT4, SOX2, and KLF4, omitting the oncogene c-Myc) has been demonstrated in the cardiac system of mice. Preclinical studies show that transient OSK expression promotes cardiomyocyte dedifferentiation, overcomes cytokinesis barriers in proliferating cardiomyocytes in vivo, and enhances cardiac repair following myocardial infarction. Because evidence is limited to animal and in vitro models, the certainty of evidence for broader physiological or clinical application remains very low.
CRISPR gene editing is being evaluated in clinical trials as a potential cure for HIV infection.
"We're seeing CRISPR now being used in a trial to cure someone who's got HIV, who's got an HIV infection, who's got AIDS." (said at 1:01:05)
The claim that CRISPR gene editing is being evaluated in clinical trials as a potential therapeutic or cure for HIV infection is supported. Clinical trials have investigated CRISPR-based therapies, such as Excision BioTherapeutics' EBT-101, which uses CRISPR-Cas9 to target and excise latent HIV-1 proviral DNA in patients. Early clinical trial findings confirmed the safety of the intervention, though it did not successfully prevent viral rebound following antiretroviral therapy interruption.
Deepak Srivastava used gene therapy to convert cardiac fibroblasts into myocytes after heart attack damage.
"And what Dr. Srivastava has done is use gene therapy—and I call it sort of cellular alchemy—to go and convert those fibroblasts into myocytes." (said at 1:02:50)
Deepak Srivastava and colleagues pioneered direct cardiac reprogramming, demonstrating that viral gene delivery of a defined cocktail of transcription factors (such as GATA4, MEF2C, and TBX5) can directly convert resident non-myocytes (cardiac fibroblasts) into functional cardiomyocyte-like cells in vitro and in vivo in rodent models of myocardial infarction, reducing scar size and improving cardiac function. Because this research is preclinical (in vitro and animal models), clinical translation in humans remains investigational.
Amy Wagers' laboratory found that GDF11 declines with age and that administering GDF11 to older mice replicates the rejuvenating benefits of young blood.
"what Amy found in her lab was a certain factor called GDF11 that is uh goes down as you age, and it appears that maybe there are factors that pull uh GDF11 out of circulation, maybe they're antibodies, maybe they're other factors. And if you give GDF11 to older mice, it seems to have all the benefits that this uh this uh blood exchange has, this young blood has." (said at 1:05:55)
The speaker accurately summarizes published findings from Amy Wagers' laboratory and collaborators. In a series of animal studies, the researchers reported that circulating levels of growth differentiation factor 11 (GDF11) decline with age in mice, and that systemic supplementation of GDF11 in aged mice reversed age-related cardiac hypertrophy, enhanced muscle stem cell function and endurance capacity, and restored neurogenesis and vascular remodeling in the brain, mirroring the restorative effects seen in heterochronic parabiosis (young-blood exchange). Because these findings are derived from preclinical animal models, the certainty is rated very low.
- supports: Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac… (Cell 2013) · cited 957x in the literature
"Using modified aptamer-based proteomics, we identified the TGF-β superfamily member GDF11 as a circulating factor in young mice that declines with age. Treatment of old mice to restore GDF11 to youthful levels recapitulated the effects of parabiosis and reversed age-related hypertrophy, revealing a therapeutic opportunity for cardiac aging." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. (Science (New York, N.Y.) 2014) · cited 844x in the literature
"Supplementation of systemic GDF11 levels, which normally decline with age, by heterochronic parabiosis or systemic delivery of recombinant protein, reversed functional impairments and restored genomic integrity in aged muscle stem cells (satellite cells). Increased GDF11 levels in aged mice also improved muscle structural and functional features and increased strength and endurance exercise capacity." (abstract, results, passage verified)
pubmedfull study (doi)
Anthony Atala has engineered organs including the bladder, urethra, and esophagus, as well as full-thickness skin for transplantation using stem cells.
"Dr. Anthony Atala, who's brilliant researcher at Wake Forest, uh, for over a decade has been using stem cells and basically differentiating those and building organs. Now, they're simple organs: it's like the bladder, um it's like a urethra, it's like an esophagus. They're mostly tubular or or containment, they're not complex organs, but he's been able to do this as well as uh basically creating skin uh that can be, you know, sort of created full dermis thickness and then used for transplantation." (said at 1:08:30)
Published clinical and preclinical studies confirm that Anthony Atala and his team at the Wake Forest Institute for Regenerative Medicine have engineered tubular and hollow organ structures, including bladders, urethras, and multi-layered/full-thickness skin constructs for transplantation. In landmark clinical studies published in The Lancet, Atala and colleagues demonstrated successful surgical reconstruction using autologous cell-seeded scaffolds for pediatric bladders (PMID 16631879) and urethras (PMID 21388673). Additionally, his group has developed multi-cellular bioprinted full-thickness skin constructs that integrate and promote healing upon transplantation in animal wound models (PMID 37792956, PMID 30755653). While the pioneering human bladder and urethra implants primarily utilized autologous biopsied and expanded tissue cells (urothelial and muscle lineages) rather than pluripotent stem cells, his broader regenerative medicine program extensively develops both stem cell- and primary progenitor-derived tissue engineering.
- supports: Tissue-engineered autologous bladders for patients needing cystoplasty. (Lancet (London, England) 2006) · cited 1841x in the literature
"Engineered bladder tissues, created with autologous cells seeded on collagen-polyglycolic acid scaffolds, and wrapped in omentum after implantation, can be used in patients who need cystoplasty." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Tissue-engineered autologous urethras for patients who need reconstruction: an observation… (Lancet (London, England) 2011) · cited 470x in the literature
"Tubularised urethras can be engineered and remain functional in a clinical setting for up to 6 years. These engineered urethras can be used in patients who need complex urethral reconstruction." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Multicellular bioprinted skin facilitates human-like skin architecture in vivo. (Science translational medicine 2023) · cited 100x in the literature
"In this study, six primary human skin cell types were used to bioprint a trilayer skin construct consisting of epidermis, dermis, and hypodermis. Transplantation of the bioprinted skin with human cells onto full-thickness wounds of nu/nu mice promoted rapid vascularization and formation of epidermal rete ridges analogous to the native human epidermis" (abstract, results, passage verified)
pubmedfull study (doi)
A genetically modified pig heart was recently transplanted into the first human recipient.
"she set on this mission probably about six, seven years ago, and uh just recently demonstrated transplanting a modified pig heart into the first human recipient." (said at 1:11:50)
A published case report from 2022 documents the first transplantation of a genetically modified porcine heart into a live human patient. A 57-year-old man with end-stage heart failure received a donor heart from a pig with 10 genetic edits (including knockouts of porcine carbohydrate antigens and insertion of human transgenes to prevent hyperacute rejection). The xenograft functioned for several weeks before developing sudden failure, and life support was withdrawn on day 60 post-transplant. As evidence from a single case report, the certainty is graded as very low.
In heterochronic parabiosis experiments connecting the circulatory systems of a young mouse and an old mouse, the old mouse becomes rejuvenated while the young mouse exhibits accelerated aging.
"If you take the circulatory system of a young mouse and an old mouse, you put them together, the old mouse gets younger and the young mouse gets older." (said at 1:05:39)
Heterochronic parabiosis experiments in mice—where the blood circulations of a young mouse and an old mouse are surgically joined—consistently demonstrate a bi-directional effect. Exposure to young circulation rejuvenates the old mouse, improving stem cell function, reducing epigenetic age, restoring tissue repair, and extending lifespan. Conversely, exposure to old circulation induces pro-geronic effects in the young mouse, including elevated cellular senescence, increased markers of the senescence-associated secretory phenotype (SASP), and accelerated vascular aging. Because these findings are derived entirely from laboratory mouse models, the certainty grade for application to humans is very low.
- supports: Rejuvenation of aged progenitor cells by exposure to a young systemic environment. (Nature 2005) · cited 2297x in the literature
"heterochronic parabiosis restored the activation of Notch signalling as well as the proliferation and regenerative capacity of aged satellite cells." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Heterochronic parabiosis regulates the extent of cellular senescence in multiple tissues. (GeroScience 2020) · cited 70x in the literature
"In heterochronic parabionts, the age-dependent increase in senescence and SASP marker expression was reduced in old mice exposed to a young environment, while senescence markers were concurrently increased in young heterochronic parabionts." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Systemic induction of senescence in young mice after single heterochronic blood exchange. (Nature metabolism 2022) · cited 112x in the literature
"aged mouse blood induces cell and tissue senescence in young animals after one single exchange." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Multi-omic rejuvenation and life span extension on exposure to youthful circulation. (Nature aging 2023) · cited 135x in the literature
"Old detached mice exhibited improved physiological parameters and lived longer than control isochronic mice. HPB drastically reduced the epigenetic age of blood and liver based on several clock models" (abstract, results, passage verified)
pubmedfull study (doi)
Vaxxinity has developed an alpha-synuclein targeting vaccine for Parkinson's disease that has completed Phase 1 and entered Phase 2 clinical trials.
"It's alpha-synuclein, it's exactly what we're targeting. And so we're entering Phase 2 uh in in that. Alzheimer's is entering Phase 3, Parkinson's is entering Phase 2. Uh it's backed by the Michael J. Fox Foundation as well." (said at 1:25:05)
Vaxxinity (formerly United Neuroscience) developed UB-312, an active immunotherapeutic / synthetic peptide vaccine targeting pathological oligomeric and fibrillar alpha-synuclein for Parkinson's disease. Clinical trials have confirmed that UB-312 successfully completed its Phase 1 clinical trial evaluating safety, tolerability, immunogenicity, and biomarker target engagement in healthy volunteers and patients with Parkinson's disease (NCT04075318). Furthermore, the Michael J. Fox Foundation provided funding/grant support to analyze clinical biomarker samples (alpha-synuclein seed amplification assays) from the UB-312 Phase 1 study, and UB-312 has advanced towards Phase 2 development.
- supports: A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine. (Movement disorders : official journal of the Movement Disorder Society 2022) · cited 55x in the literature
"UB-312 is a synthetic αSyn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligomeric and fibrillar αSyn, making UB-312 a potential immunotherapeutic for synucleopathies." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological… (Nature medicine 2024) · cited 47x in the literature
"Here this 44-week, randomized, placebo-controlled, double-blind, single-center phase 1 study investigated safety, tolerability and immunogenicity of UB-312, an active immunotherapeutic targeting pathological αSyn, in patients with PD... These data support further UB-312 development. ClinicalTrials.gov: NCT04075318 ." (abstract, results, passage verified)
pubmedfull study (doi)
12 No source found (not proven false)
Cristiano Ronaldo returned to play in two and a half weeks instead of being out for three months due to stem cell treatment.
"You know, someone like Cristiano Ronaldo was supposed to be out for three months, it was two and a half weeks and he's back on because of stem cells." (said at 0:01:24)
No published record matching the claim that Cristiano Ronaldo received stem cell treatment allowing him to return to play in two and a half weeks instead of three months was located; this does not prove the claim false.
Jack Nicklaus underwent stem cell treatment for severe back pain instead of spinal fusion and was able to return to playing golf and tennis at age 82.
"I met, you know, Jack Nicklaus, one of the greatest golfers of all time. He couldn't stand for more than 10 minutes, his pain was so severe. They were going to, you know, lock up, you know, give him a spinal fusion, which as I'm sure you know doesn't usually work, at least half the time, and if it does, gives you limited mobility. He did stem cells instead, and here he was, 82 years old, now playing golf and tennis." (said at 0:05:28)
No published record matching the claim that Jack Nicklaus underwent stem cell treatment for severe back pain in place of spinal fusion and returned to golf and tennis at age 82 was located; this does not prove the claim false. While Nicklaus has spoken publicly in media interviews about receiving experimental adipose-derived stem cell therapy in Germany for chronic back pain, this anecdotal clinical account has not been published as a peer-reviewed case report or formal clinical study.
Keeping bedroom temperature at approximately 65 degrees Fahrenheit allows individuals to reach deeper sleep stages.
"I keep the temperature about 65 degrees, which allows you to go deeper." (said at 0:12:45)
No published record matching the claim that keeping bedroom temperature at approximately 65 degrees Fahrenheit allows individuals to reach deeper sleep stages was located; this does not prove the claim false.
During World War II, a doctor administered saline believing it was morphine to wounded soldiers running out of morphine, and 90% of them experienced pain relief without going into shock.
"It was actually a nurse that changed the world: she handed him saline solution and said, "Oh, we got some more morphine." Since he believed it, he told these patients with total certainty, "You'll be out of pain in the next minute or two, and you're going to be fine." Well, none of them went into shock, 90% of them were out of pain with no drugs." (said at 0:17:08)
No published record matching the claim that 90% of wounded World War II soldiers experienced pain relief and avoided shock after receiving saline substituted for morphine was located; this does not prove the claim false. Published clinical literature on placebo response under high stress (such as Henry Beecher's work following WWII) documented that placebos are effective in severe pathological pain, but reported response rates of approximately 30–35%, rather than 90%.
Harvard studies showed that subjects given a barbiturate but told it was a large red amphetamine pill exhibited bodily stimulation rather than sedation.
"I'm sure you know Harvard's done studies where they take someone and give them a real drug, not a placebo, a barbiturate that's going to knock you on the ground to slow you down, and they go, "Big giant red pill, this is amphetamine. You're going to be prepared what's going to do for you." To a man or a woman, their bodies speed up." (said at 0:18:15)
No published record matching the claim that Harvard studies administered a barbiturate disguised as an amphetamine and found that every subject's physiological response reversed to stimulation was located; this does not prove the claim false.
Among people in Peter Diamandis's demographic undergoing full-body preventative MRI screening, 2% have an undetected cancer, 2.5% have an undetected aneurysm, and 14.4% have an actionable finding.
"And it turns out historically for people in my age group, 2% have a cancer they don't know about, 2.5% have an aneurysm they don't know about, and 14.4% have something that's found that you need to take action on." (said at 0:21:53)
No published record matching the claim that 2% have an undetected cancer, 2.5% have an undetected aneurysm, and 14.4% have an actionable finding in this screening demographic was located; this does not prove the claim false.
The strength of a placebo response increases with the size and invasiveness of the intervention, with larger pills producing stronger effects than smaller pills, and sham injections producing stronger effects than pills.
"Now, first of all, the size of the placebo, the size of our intervention changes everything: a little pill, certain reaction; a big pill, more; an injection, even more." (said at 0:17:46)
No published record matching the claim that the magnitude of a placebo response increases with intervention size or invasiveness (such as larger pills producing greater effects than smaller pills, or sham injections producing stronger effects than oral placebos) was located; this does not prove the claim false.
Commercial NMN supplement products break down and become inert within 30 to 45 days.
"he said, "It breaks down in 30 to 45 days. So by the time somebody gets this product, it's usually inert."" (said at 0:32:48)
No published record matching the claim that commercial nicotinamide mononucleotide (NMN) supplement products break down and become inert within 30 to 45 days was located; this does not prove the claim false.
Astronauts on the International Space Station for six to twelve months experience accelerated DNA damage and chromosomal instability due to radiation exposure.
"astronauts that have gone on the International Space Station and then stayed there for six months to a year, and um how they're, you know, they're being exposed to cosmic radiation and other types of solar things, um and uh it, you know, essentially being in space is causing uh accelerated DNA damage, there's chromosomal instability, it's it's, you know, it's affecting the aging process." (said at 0:57:22)
No published record matching the claim that astronauts on the International Space Station for six to twelve months experience accelerated DNA damage and chromosomal instability due to radiation exposure was located; this does not prove the claim false.
A study testing products from six commercial NMN supplement companies found no NMN present in any of the tested products.
"with Dr. Sinclair, we studied six companies. We took their products to see how much NMN are you really getting, and there was none in any of the products." (said at 0:32:20)
No published record matching the specific claim that a study co-authored by Dr. Sinclair evaluated six commercial NMN supplement companies and found zero NMN present across all products was located; this does not prove the claim false.
On average, scientific and medical progress currently extends human life expectancy by approximately one quarter of a year for every year lived.
"But on the average, every year that you live, science extends your life by about a quarter of a year. So for every four years, you're adding an additional year." (said at 0:45:40)
No published record matching the claim that science extends life expectancy by a quarter of a year for every year lived was located; this does not prove the claim false.
Dean Kamen's team has manufactured a bone-ligament-bone construct derived from pluripotent stem cells for knee or ankle replacement.
"what Dean has done already is actually go from these pluripotent stem cells to a bone-ligament-bone construct, it can be used for knee or ankle replacement." (said at 1:14:03)
No published record matching the claim that Dean Kamen's team has manufactured a pluripotent stem cell-derived bone-ligament-bone construct for knee or ankle replacement was located; this does not prove the claim false.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.